Reliance Life Sciences offers the following Molecular Medicine services:

  • Molecular Microbiology
  • Cytogenetics and Molecular Genetics
  • Flow Cytometry
  • Anatomic Pathology and Cytopathology
  • Predictive Diagnostics
  • Companion Diagnostics
  • Pharmacogenomics
The Molecular Medicine laboratory is accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and the College of American Pathologists (CAP).

Molecular Microbiology

Reliance Life Sciences provides DNA/RNA based diagnostics services for infectious diseases, qualitative tests for detection of viruses – Hepatitis panel (A, B, C), human immunodeficiency virus, Herpes simplex, Cytomegalovirus, Epstein barr virus, Parvovirus, BK virus, Dengue and Chikungunya. Reliance Life Sciences offers tests to detect bacterial / other pathogens like TB, Chlamydia, Rubella and Toxoplasma, real-time PCR (quantitative) to estimate HBV, HIV, HCV, CMV and BK viral load and nucleotide sequencing based methods for HBV, HCV and HPV genotype identification.

Reliance Life Sciences offers screening of various viral antigens such as CMV IgG & IgM, HIV, HBsAg, HBcAb, Syphilis and HTLV using Enzyme Linked Immunosorbent Assay (ELISA) that assist in diagnosis and prognosis of disease in early infection.

To know more about the Molecular Microbiology services available, click here.

Cytogenetics and Molecular Genetics

Reliance Life Sciences is involved in cytogenetic research and provides cytogenetic testing services using modified Karyotyping and Fluorescence In-Situ Hybridization (FISH) based assays to detect numerical and structural chromosomal abnormalities, including translocations, amplifications and micro-deletions in peripheral blood cells, bone marrow, products of conception, chorionic villi, amniotic fluid and cord blood.

Prenatal diagnosis for all karyotypic aberrations and rapid FISH based assays for Down's syndrome, Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia, add to the repertoire of essential high-end molecular genetic testing services offered by Reliance Life Sciences.

Specialized molecular testing is also provided for HLA typing, exon deletions for Duchenne Muscular Dystropy, Mitochondrial mutations associated with various neurological diseases, mutations associated with Spino-cerebellar Ataxia, Huntington’s disease, Cystic Fibrosis, HBV Drug Resistance, Beta Thalassemia mutations identification in globin gene and Y chromosome deletion for male infertility investigations.

To know more about the Cytogenetic testing services available, click here

Flow Cytometry based diagnostics:

At Reliance Life Sciences, flow cytometry based estimation of CD4 and CD8 counts in immunocompromised patients, such as HIV patients or people on immunosuppressive drugs are offered

Anatomic Pathology & Cytopathology

Reliance Life Sciences is primarily involved in diagnosis of various benign and malignant lesions, including Immunohistochemistry for diagnosis of primary & metastatic tumors, to determine the prognosis of the disease and importantly in personalized medicine in cases such as gastro-intestinal tumors, brain tumors, lung tumors, breast carcinomas. Besides, this lab also offers screening for cervical cancer via gynecologic cervical cytology.

To know more about the Anatomic pathology services available, click here

Predictive Diagnostics

Reliance Life Sciences is involved in Predictive Diagnostic testing in the field of Oncology, with the objective of predicting increased risk of developing a disease in the future based on a test done on an asymptomatic person (person who appears normal). Positive result only provides information about a person's risk of developing cancer. Negative result indicates the individual's risk of cancer is the same as that of general population. Reliance Life Sciences was the first organization to introduce BRCA 1/ BRCA 2 mutations testing for familial breast cancer in India. Reliance Life Sciences uses state-of-the-art technology of DNA sequencing - 'a gold standard', to detect mutations. This test is 100 percent sensitive and specific. Reliance Life Sciences offers both pre- and post-test genetic counseling and reports both, the alterations depicting the polymorphisms and mutations observed. We have competitive Turn around time (TAT) for reporting of BRCA1/BRCA2 (fifteen days). Reliance Life Sciences has launched India’s first portal for Breast cancer genomics to help the medical fraternity to predict familial and/ or early onset breast cancer in Indian women.

Reliance Life Sciences also offers Preimplantation Genetic Diagnosis (PGD) for Chromosomal aberrations (chromosomes 13, 18, 21, X & Y), Beta Thalassemia, Sickle cell anemia. It is a highly advanced, complex and technically demanding procedure and is an attractive means of preventing heritable genetic disease, thereby eliminating the dilemma of pregnancy termination following unfavorable prenatal diagnosis.

Reliance Life Sciences also provides predictive tests for RET gene mutations for familial Medullary Thyroid Cancer and Human Papilloma Virus (HPV) detection and typing by nucleotide sequencing, for predicting increased risk of cervical cancer.

Tests are also available for predicting the probability of an individual for stroke, heart attack etc. These tests study gene mutations in three Cardio-Vascular diseases (CVD) risk markers i.e. Factor V Leiden, MTHFR and Prothrombin, which accounts to around 45% of all the thrombotic risk factors.

To know more about predictive diagnostics testing services available, click here

Companion Diagnostics

Reliance Life Sciences is focusing on the contemporary field of Theranostics, with equivalent emphasis on diagnostics and therapy. Thus, selection of patients for optimal treatment with targeted therapy such as monoclonal antibodies or small molecules (like tyrosine kinase inhibitors) require molecular diagnostics to detect KRAS mutations in metastatic colorectal cancers, EGFR mutations in non-small cell lung cancers, or MGMT methylation to select patients for treatment with Temozolomide. These and several tests grouped in the field of Theranostics are offered at Reliance Life Sciences.

To know more about Companion Diagnostic services available, click here


Reliance Life Sciences also provides services to study the genetic variability that affects drug metabolism and response and hence in turn may affect the efficacy of the patient’s current and/or future treatments. In the realm of cardiovascular disease, optimal Warfarin dosage for individual patient, is offered via VKORC1 and CYP2C9 allelotyping. UGT1A1 genotype study is used to ascertain the toxicity profile for Irinotecan

To know more about pharmacogenomic services available, click here